

**Appendix Table F72. Dry mouth after pharmacological treatments for UI when compared to each other**

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Zinner, 2005 <sup>412</sup>	Darifenacin ER	15mg/day	Oxybutynin	5 mg 3 times/day	0/19	7/19	0.1(0.0; 1.1)	-0.37 (-0.59; -0.15)
Abrams, 1998 <sup>226</sup>	Oxybutynin	5mg thrice daily	Tolterodine	2mg twice daily	102/118	59/118	1.7(1.4; 2.1)	0.36 (0.26; 0.47)
Drutz, 1999 <sup>283</sup>	Oxybutynin	5mg thrice a day	Tolterodine	2mg twice a day	77/112	33/109	2.3(1.7; 3.1)	0.38 (0.26; 0.51)
Appell, 2001 <sup>230</sup>	Oxybutynin	10mg/day	Tolterodine LA	2mg twice daily	52/185	64/193	0.8(0.6; 1.2)	-0.05 (-0.14; 0.04)
Lee, 2002 <sup>335</sup>	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	72/116	39/112	1.8(1.3; 2.4)	0.27 (0.15; 0.40)
Halaska, 2003 <sup>302</sup>	Trospium	40mg/day	Oxybutynin	10mg/day	87/267	45/90	0.7(0.5; 0.9)	-0.17 (-0.29; -0.06)
Halaska, 2003 <sup>302</sup>	Trospium	20mg twice daily	Oxybutynin	5mg twice daily	87/267	45/90	0.7(0.5; 0.9)	-0.17 (-0.29; -0.06)
Diokno, 2003 <sup>273</sup>	Oxybutynin	10mg/d	Tolterodine ER	4mg/d	116/391	89/399	1.3(1.0; 1.7)	0.07 (0.01; 0.13)
Homma, 2003 <sup>311</sup>	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	131/244	80/239	1.6(1.3; 2.0)	0.20 (0.12; 0.29)
Chapple, 2004 <sup>265</sup>	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	0/41	9/37	0.0(0.0; 0.8)	-0.24 (-0.38; -0.10)
Chapple, 2004 <sup>265</sup>	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	5/37	9/37	0.6(0.2; 1.5)	-0.11 (-0.28; 0.07)
Chapple, 2004 <sup>265</sup>	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	5/35	9/37	0.6(0.2; 1.6)	-0.10 (-0.28; 0.08)
Chapple, 2004 <sup>265</sup>	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	14/37	9/37	1.6(0.8; 3.1)	0.14 (-0.07; 0.34)
Chapple, 2004 <sup>54</sup>	Solifenacin	5mg daily	Tolterodine	2mg twice daily	39/279	49/266	0.8(0.5; 1.1)	-0.04 (-0.11; 0.02)
Chapple, 2004 <sup>54</sup>	Solifenacin	10mg daily	Tolterodine	2mg twice daily	57/269	49/266	1.2(0.8; 1.6)	0.03 (-0.04; 0.10)

**Appendix Table F72. Dry mouth after pharmacological treatments for UI when compared to each other (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Homma, 2004 <sup>310</sup>	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	75/122	42/114	1.7(1.3; 2.2)	0.25 (0.12; 0.37)
Sand, 2004 <sup>373</sup>	Oxybutynin	10mg/day	Tolterodine	2mg b.i.d.	43/152	55/163	0.8(0.6; 1.2)	-0.05 (-0.16; 0.05)
Chapple, 2005 <sup>258</sup>	Darifenacin IR	2.5 t.i.d.	Oxybutynin IR	2.5 t.i.d.	4/8	8/8	0.5(0.3; 1.0)	-0.50 (-0.86; -0.14)
Zinner, 2005 <sup>412</sup>	Darifenacin ER	30mg/day	Oxybutynin	5 mg 3 times/day	7/19	7/19	1.0(0.4; 2.3)	0.00 (-0.31; 0.31)
Armstrong, 2005 <sup>231</sup>	Oxybutynin	10mg/day	Tolterodine ER	4mg daily	110/391	86/399	1.3(1.0; 1.7)	0.07 (0.01; 0.13)
Armstrong, 2007 <sup>232</sup>	Oxybutynin	10mg qd	Tolterodine ER	2mg qd	169/576	64/193	0.9(0.7; 1.1)	-0.04 (-0.11; 0.04)
Armstrong, 2007 <sup>232</sup>	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	169/576	89/399	1.3(1.1; 1.6)	0.07 (0.02; 0.13)
Chapple, 2007 <sup>263</sup>	Solifenacin	5mg daily	Tolterodine	4mg daily	82/578	69/599	1.2(0.9; 1.7)	0.03 (-0.01; 0.06)
Chapple, 2007 <sup>259</sup>	Fesoterodine	8mg daily	Tolterodine	4mg daily	97/288	49/290	2.0(1.5; 2.7)	0.17 (0.10; 0.24)
Chapple, 2007 <sup>259</sup>	Fesoterodine	4mg daily	Tolterodine	4mg daily	59/272	49/290	1.3(0.9; 1.8)	0.05 (-0.02; 0.11)
Yamaguchi, 2007 <sup>410</sup>	Solifenacin	5mg daily	Propiverine	20mg daily	67/400	103/402	0.7(0.5; 0.9)	-0.09 (-0.14; -0.03)
Yamaguchi, 2007 <sup>410</sup>	Solifenacin	10mg daily	Propiverine	20mg daily	130/385	103/402	1.3(1.1; 1.6)	0.08 (0.02; 0.15)
Chapple, 2008 <sup>260</sup>	Fesoterodine	8mg daily	Tolterodine	4mg daily	97/287	49/290	2.0(1.5; 2.7)	0.17 (0.10; 0.24)
Choo, 2008 <sup>268</sup>	Solifenacin	5mg once daily	Tolterodine IR	2mg twice daily	9/120	22/118	0.4(0.2; 0.8)	-0.11 (-0.20; -0.03)
Choo, 2008 <sup>268</sup>	Solifenacin	10mg once daily	Tolterodine IR	2mg twice daily	23/119	22/118	1.0(0.6; 1.8)	0.01 (-0.09; 0.11)
Sand, 2009 <sup>372</sup>	Fesoterodine	8mg daily	Tolterodine	4mg daily	155/452	37/227	2.1(1.5; 2.9)	0.18 (0.11; 0.24)

**Appendix Table F72. Dry mouth after pharmacological treatments for UI when compared to each other (continued)**

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Sand, 2009 <sup>372</sup>	Fesoterodine	4mg daily	Tolterodine	4mg daily	89/434	37/227	1.3(0.9; 1.8)	0.04 (-0.02; 0.10)
Herschorn, 2010 <sup>475</sup>	Fesoterodine	4-8mg once daily	Tolterodine ER	4mg once daily	189/679	112/684	1.7(1.4; 2.1)	0.11 (0.07; 0.16)
Herschorn, 2010 <sup>304</sup>	Solifenacin	5mg once daily	Oxybutynin IR	5mg 3 times daily	24/68	53/64	0.4(0.3; 0.6)	-0.48 (-0.62; -0.33)
Junemann, 2000 <sup>320</sup>	Trospium	20mg twice daily	Tolterodine	2mg twice daily	22/76	21/77	1.1(0.6; 1.8)	0.02 (-0.13; 0.16)
Kaplan, 2010 <sup>322</sup>	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 mg once daily	270/963	127/974	2.2(1.8; 2.6)	0.15 (0.11; 0.19)
NCT00444925, <sup>58</sup>	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	189/685	112/690	1.7(1.4; 2.1)	0.11 (0.07; 0.16)